You are tracking the obesity drug pipeline and want to know where survodutide stands against the current leader. Survodutide (BI 456906) and tirzepatide are both dual-receptor agonists, but they activate different receptor pairs. Tirzepatide combines GIP and GLP-1, producing 22.5% weight loss at 72 weeks (SURMOUNT-1). Survodutide combines GLP-1 and glucagon, achieving up to 14.9% weight loss at 46 weeks in Phase 2 and 47 to 62% MASH resolution in a separate Phase 2 liver trial. Tirzepatide is FDA-approved. Survodutide is in Phase 3 with obesity results expected in the first half of 2026 (le Roux et al., Lancet Diabetes Endocrinol, 2024; Jastreboff et al., NEJM, 2022).
| Feature | Tirzepatide | Survodutide |
|---|---|---|
| Receptors | GIP + GLP-1 | GLP-1 + Glucagon |
| Developer | Eli Lilly | Boehringer Ingelheim + Zealand Pharma |
| Brand names | Mounjaro, Zepbound | None yet |
| Max weight loss | 22.5% at 72 weeks | 14.9% at 46 weeks (Phase 2) |
| MASH resolution | No dedicated trial | 47 to 62% (Phase 2) |
| Liver fat reduction | ~55% (indirect) | Up to 87% (direct) |
| Discontinuation for AEs | 4.3 to 7.1% | 20 to 29% (Phase 2) |
| Approval status | FDA-approved | Phase 3 (results H1 2026) |
| FDA designation | N/A | Breakthrough Therapy (MASH) |
For current tirzepatide dosing, use our tirzepatide dosage calculator.
Get your custom peptide protocol:
- Tailored to your body and goals
- Precise dosing and cycle length
- Safe stacking combinations
- Backed by peer-reviewed studies
- Ready in under 2 minutes
How Each Drug Works: The Receptor Difference
Both drugs are dual-receptor agonists. The specific receptors they target produce fundamentally different metabolic effects.
Tirzepatide: GIP + GLP-1 (The Twincretin)
Tirzepatide activates GIP and GLP-1 receptors simultaneously. GLP-1 suppresses appetite and slows gastric emptying. GIP enhances insulin sensitivity and optimizes how adipose tissue stores and releases fat. The combination produces greater weight loss than GLP-1 alone, as demonstrated by SURMOUNT-5: tirzepatide 20.2% versus semaglutide (GLP-1 only) 13.7% (NEJM, 2025).
The GIP component primarily targets appetite regulation and glucose handling. It does not directly affect liver metabolism or energy expenditure in the way glucagon does.
Survodutide: GLP-1 + Glucagon (The Liver Targeter)
Survodutide activates GLP-1 and glucagon receptors. GLP-1 provides appetite suppression (the shared pathway). Glucagon adds three distinct metabolic effects.
First, glucagon increases hepatic energy expenditure. Your liver burns more calories at rest. Second, glucagon stimulates fat oxidation in the liver, directly clearing stored fat from hepatocytes. Third, glucagon promotes thermogenesis, increasing whole-body energy output.
Think of tirzepatide as turning down the calorie intake dial. Survodutide turns down the intake dial (via GLP-1) and turns up the calorie burning dial (via glucagon). The liver gets a targeted dose of metabolic activation that no GIP-based drug provides (le Roux et al., Lancet Diabetes Endocrinol, 2024).
The Glucagon Difference for Liver Disease
The glucagon pathway is what makes survodutide a MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) drug rather than just a weight loss drug. MASH involves liver inflammation and fibrosis driven by excessive hepatic fat accumulation. Clearing that fat is the therapeutic target.
Tirzepatide reduces liver fat indirectly: you lose weight, and some of that fat comes from the liver. The reduction is approximately 55% in studies that measured hepatic fat. Survodutide reduces liver fat both indirectly (weight loss) and directly (glucagon-driven hepatic fat oxidation), achieving up to 87% reduction in Phase 2 MASH trials. That 32-percentage-point difference matters for patients whose liver is the primary concern.
Weight Loss Results Compared
Comparing weight loss across different trial phases and durations requires caution. Survodutide's Phase 2 data cannot be directly equated with tirzepatide's Phase 3 data.
Tirzepatide: Proven Efficacy
SURMOUNT-1 enrolled 2,539 adults and followed them for 72 weeks. The results are the benchmark for obesity pharmacotherapy (Jastreboff et al., NEJM, 2022).
| Dose | Weight Loss | Participants Achieving 20%+ |
|---|---|---|
| 5 mg | 15.0% | 27% |
| 10 mg | 19.5% | 46% |
| 15 mg | 22.5% | 56% |
These are Phase 3 results from a large, diverse population with 72-week follow-up. The data is mature and published in the NEJM.
Survodutide: Promising Phase 2
The survodutide Phase 2 obesity trial enrolled 387 participants across four dose groups for 46 weeks (le Roux et al., Lancet Diabetes Endocrinol, 2024).
| Dose | Weight Loss (46 wk) |
|---|---|
| 0.6 mg | 6.2% |
| 2.4 mg | 12.5% |
| 3.6 mg | 13.2% |
| 4.8 mg | 14.9% |
| Placebo | 2.8% |
The 14.9% at 46 weeks is strong for a Phase 2 trial, but the comparison to tirzepatide's 22.5% at 72 weeks is imperfect. Phase 2 trials use smaller, more selected populations. The 46-week duration is 26 weeks shorter than SURMOUNT-1. Higher doses in Phase 3 (the SYNCHRONIZE program) may narrow the gap.
Can Survodutide Match Tirzepatide's Weight Loss?
The Phase 3 SYNCHRONIZE program tests survodutide at higher doses over longer durations than Phase 2. SYNCHRONIZE-1 enrolls adults with obesity; SYNCHRONIZE-2 targets type 2 diabetes with obesity (PMC, 2024). Results are expected in the first half of 2026.
Phase 2 to Phase 3 weight loss often varies by 2 to 4 percentage points. If survodutide's Phase 3 results land at 16 to 18% at 52 to 72 weeks, the gap with tirzepatide narrows to 4 to 6 percentage points. Closing it entirely seems unlikely given the GI tolerability challenges discussed below.
A meta-analysis pooling all survodutide RCTs confirmed the dose-response relationship and overall efficacy (PMC, 2025).
The Liver Advantage: Survodutide's Unique Value
Liver data is where survodutide separates itself from every other obesity drug in development, including tirzepatide.
MASH Resolution Data (Phase 2 NEJM)
The Phase 2 MASH trial tested survodutide in adults with biopsy-confirmed MASH (fibrosis stages 1 to 3). Results published in the NEJM showed (NEJM, 2024):
| Dose | MASH Resolution | Liver Fat Reduction |
|---|---|---|
| 2.4 mg | 47% | ~75% |
| 4.8 mg | 62% | Up to 87% |
| Placebo | 14% | Minimal |
MASH resolution means the liver biopsy no longer shows the inflammatory pattern that defines the disease. A 62% resolution rate at 4.8 mg is among the highest reported for any drug in MASH clinical trials. The FDA granted survodutide Breakthrough Therapy designation for MASH based on these results (Boehringer Ingelheim, 2024).
LIVERAGE Phase 3 MASH Trials
Two Phase 3 MASH trials are underway. LIVERAGE enrolls approximately 1,800 adults with MASH fibrosis stages 2 to 3. LIVERAGE-Cirrhosis enrolls approximately 1,590 adults with compensated MASH cirrhosis (stage 4 fibrosis).
These are among the largest MASH trials ever conducted. If Phase 3 confirms the Phase 2 results (47 to 62% resolution), survodutide could become the first drug approved specifically for MASH with advanced fibrosis. The FDA's Breakthrough Therapy designation supports an expedited review pathway.
Tirzepatide's Limited Liver Data
Tirzepatide reduces liver fat by approximately 55% as a secondary effect of overall weight loss. No dedicated MASH trial for tirzepatide has reported results. The SYNERGY-NASH trial is in progress but is not the primary focus of Eli Lilly's tirzepatide program.
For patients whose main concern is liver health (NAFLD, MASH, elevated liver enzymes), survodutide's glucagon-driven hepatic targeting provides a mechanistic advantage that tirzepatide does not offer. For patients whose main concern is maximum weight loss, tirzepatide's proven 22.5% remains unmatched.
Side Effects and Tolerability: A Critical Difference
Tolerability is survodutide's biggest challenge and the primary risk to its commercial success.
| Parameter | Tirzepatide (SURMOUNT-1) | Survodutide (Phase 2 Obesity) |
|---|---|---|
| Any GI adverse event | 39 to 49% | ~75% |
| Nausea | 24 to 31% | 40 to 50% |
| Diarrhea | 17 to 23% | 25 to 35% |
| Vomiting | 5 to 12% | 15 to 25% |
| Discontinuation for AEs | 4.3 to 7.1% | 20 to 29% |
The discontinuation rate gap is striking. Between 20% and 29% of survodutide participants dropped out due to adverse events in Phase 2, compared to 4.3 to 7.1% for tirzepatide in Phase 3. GI side effects are the primary reason.
Glucagon receptor activation directly stimulates gastric acid secretion and GI motility, which compounds the GI burden already created by GLP-1. Tirzepatide's GIP component may actually buffer GI symptoms rather than amplify them. This tolerability difference could limit survodutide's use in the general obesity population, steering it toward MASH patients where the liver benefit justifies the GI cost.
The Phase 3 SYNCHRONIZE program uses optimized dose titration that may reduce discontinuation rates. Phase 2 trials sometimes escalate doses faster than eventual commercial protocols. If SYNCHRONIZE achieves discontinuation rates below 15%, survodutide becomes more competitive (PMC, 2024).
Developer and Trial Programs
Understanding who is developing each drug and what their trial programs look like provides context for availability timelines.
Tirzepatide: Eli Lilly
Eli Lilly's tirzepatide program spans obesity (SURMOUNT), type 2 diabetes (SURPASS), and cardiovascular outcomes (SURPASS-CVOT). The drug received FDA approval in May 2022 (Mounjaro for T2D) and November 2023 (Zepbound for obesity). It is available globally in branded and compound formulations.
Eli Lilly has built a complete commercial infrastructure around tirzepatide, including manufacturing capacity, insurance partnerships, and patient support programs. This gives tirzepatide an unmatched head start.
Survodutide: Boehringer Ingelheim + Zealand Pharma
Survodutide is co-developed by Boehringer Ingelheim (one of the largest privately held pharmaceutical companies) and Zealand Pharma (a Danish peptide specialist). The trial program includes:
SYNCHRONIZE-1 and SYNCHRONIZE-2: Phase 3 obesity trials. LIVERAGE and LIVERAGE-Cirrhosis: Phase 3 MASH trials (approximately 3,390 participants combined). SYNCHRONIZE CVOT: cardiovascular outcomes trial (JACC Heart Fail, 2024).
Phase 3 obesity results are expected H1 2026. If positive, Boehringer Ingelheim could file for FDA approval in late 2026 or early 2027. Earliest commercial availability: 2027 to 2028 for obesity; potentially sooner for MASH given the Breakthrough Therapy designation.
Survodutide vs Mazdutide: The Other GLP-1/Glucagon Drug
Both survodutide and mazdutide target the same receptor pair (GLP-1 + glucagon). They are different molecules from different companies with different development strategies.
| Aspect | Survodutide | Mazdutide |
|---|---|---|
| Developer | Boehringer Ingelheim + Zealand Pharma | Innovent Biologics + Eli Lilly |
| Approval | None yet (Phase 3) | NMPA-approved (China only) |
| MASH program | LIVERAGE Phase 3 (3,390 participants) | None announced |
| Weight loss | 14.9% at 46 weeks (Phase 2) | 20.1% at 60 weeks (GLORY-2) |
| Discontinuation | 20 to 29% | 0.5 to 1.5% |
| Global strategy | FDA submission planned | No FDA plans announced |
Mazdutide shows superior weight loss and dramatically better tolerability in its trials. Survodutide has the MASH data and the global regulatory strategy. A third GLP-1/glucagon drug, cotadutide (AstraZeneca), is less advanced in development. For the oral GLP-1 comparison, see our orforglipron vs tirzepatide analysis.
Who Should Care About Survodutide?
Survodutide is not available today. Its relevance depends on your clinical situation and time horizon.
Patients with MASH or significant liver fat. This is survodutide's strongest target population. If you have biopsy-confirmed MASH with fibrosis, survodutide's 47 to 62% resolution rate and up to 87% liver fat reduction represent a potential breakthrough. No currently available drug matches these numbers.
Those who need liver-targeted metabolic benefits. If your blood work shows elevated ALT/AST, fatty liver on imaging, or diagnosed NAFLD, the glucagon-mediated hepatic fat clearance that survodutide provides addresses the root pathology directly.
Pipeline watchers and researchers. The SYNCHRONIZE Phase 3 readout in H1 2026 will be one of the most important obesity drug data events of the year. If survodutide closes the weight loss gap with tirzepatide while maintaining its MASH efficacy, it becomes a serious competitor.
Patients with tirzepatide intolerance. If you cannot tolerate tirzepatide's GI side effects (4.3 to 7.1% discontinuation), survodutide's higher GI burden (20 to 29%) makes it unlikely to be a better option for you. However, the different receptor mechanism may suit individuals whose specific GI response differs. For tirzepatide long-term safety data, see our dedicated review. For other comparisons, see our retatrutide vs tirzepatide analysis.
Frequently Asked Questions
Is survodutide better than tirzepatide for weight loss?
No, based on current data. Tirzepatide produces 22.5% weight loss at 72 weeks (SURMOUNT-1, Phase 3). Survodutide produces 14.9% at 46 weeks (Phase 2). The comparison is imperfect due to different trial phases and durations. Phase 3 results (SYNCHRONIZE, expected H1 2026) may narrow the gap, but survodutide's high GI-related discontinuation rate (20 to 29%) is a significant challenge.
When will survodutide be available?
Phase 3 obesity results (SYNCHRONIZE) are expected in the first half of 2026. If positive, an FDA submission could occur in late 2026 or early 2027, with approval potentially in 2027 to 2028. MASH approval may come sooner given the FDA Breakthrough Therapy designation. Survodutide is not available through any legal channel today. No research-grade supply exists for consumers.
Does survodutide help with fatty liver?
Yes. Survodutide's Phase 2 MASH trial (published in NEJM) showed 47% MASH resolution at 2.4 mg and 62% at 4.8 mg, versus 14% for placebo. Liver fat reduction reached up to 87%. These are among the strongest liver outcomes reported for any drug in MASH clinical trials. Phase 3 LIVERAGE trials (3,390 participants) will confirm these results.
What are survodutide's side effects?
GI side effects are the primary concern. In Phase 2, approximately 75% of participants experienced GI adverse events (nausea, diarrhea, vomiting), and 20 to 29% discontinued due to adverse events. This is significantly higher than tirzepatide's 4.3 to 7.1% discontinuation rate. Phase 3 uses optimized dose titration that may improve tolerability. No unique serious safety signals have emerged beyond GI events.
Is survodutide the same as mazdutide?
No. Both are GLP-1/glucagon dual agonists, but they are different molecules. Survodutide (BI 456906) is from Boehringer Ingelheim and Zealand Pharma, in global Phase 3. Mazdutide (IBI362) is from Innovent Biologics and Eli Lilly, approved in China. They differ in dose ranges, tolerability profiles (survodutide 20 to 29% discontinuation vs mazdutide 0.5 to 1.5%), and development strategy.
How does survodutide compare to semaglutide?
No head-to-head trial exists. Survodutide's 14.9% weight loss at 46 weeks (Phase 2) is comparable to semaglutide's 12.4% at 68 weeks (STEP 1). Survodutide's key advantage over semaglutide is the glucagon component: direct liver fat clearance, increased energy expenditure, and 47 to 62% MASH resolution. Semaglutide has no dedicated MASH trial data showing comparable liver outcomes.
The Bottom Line
Survodutide and tirzepatide serve different primary needs. Tirzepatide is the proven weight loss leader: FDA-approved, 22.5% weight loss at 72 weeks, low discontinuation rate (4.3 to 7.1%), and global availability. Survodutide's value lies in its liver: 47 to 62% MASH resolution, up to 87% liver fat reduction, and a glucagon-driven mechanism that directly targets hepatic steatosis.
The tolerability gap is the main concern. Survodutide's 20 to 29% discontinuation rate in Phase 2 limits its appeal for general weight loss. If Phase 3 (SYNCHRONIZE, H1 2026) reduces that rate through optimized titration while maintaining liver efficacy, survodutide could establish a distinct niche for patients with MASH and metabolic liver disease.
Use our tirzepatide dosage calculator for current treatment planning. For the GLP-1/glucagon comparison in China, see mazdutide vs tirzepatide. For the oral GLP-1 option, see orforglipron vs tirzepatide. For tirzepatide before and after results, visit our outcomes page.
Not Sure Which Peptide Protocol Is Right for You?
Take our 2-minute quiz for a personalized recommendation based on your goals and health profile.
Start the Quiz →